Results of INFORM Study Released at San Antonio Breast Cancer Symposium
Susan G. Komen®, the world’s leading
breast cancer organization, today welcomed the results of the INFORM trial that
were announced at the 2019 San Antonio Breast Cancer Symposium. The
Komen-funded INFORM trial led by Dr. Nadine Tung shows that HER2-negative
patients with a BRCA1/2 gene mutation have multiple effective treatment
Tung and colleagues sought to determine if cisplatin chemotherapy is a more
effective treatment than the current, standard of care treatment, chemotherapy
with doxorubicin and cyclophosphamide (commonly referred to as “AC”). Prior retrospective
studies, which looked at treatment that has already occurred as part of the
study, had indicated that cisplatin chemotherapy might work better than AC. The
INFORM clinical trial was the first prospective study, or a study that evaluates
treatment moving forward, to actually test this idea.
HER2 negative breast cancer patients with BRCA1/2 mutations, the INFORM trial
confirmed that cisplatin chemotherapy is not more effective than standard
chemotherapy with doxorubicin and cyclophosphamide. The results suggest that BRCA
carriers may respond to both types of chemotherapy – which kill cancer cells by
damaging DNA – giving them multiple options to treat their cancer,” said Dr.
Tung. Prospective studies are essential for improving clinical practice.
added, “Funding from Susan G. Komen was essential for this work.” Funded in
part by a Komen Opportunity Grant, the INFORM trial is also part of the Translational
Breast Cancer Research Consortium (TBCRC), which has been supported by Komen for
more than 10 years.
Victoria Wolodzko, senior vice president of
Mission at Susan G. Komen, added, “Patients with BRCA mutations face many challenges,
especially those in rural or underserved areas. This work confirms that physicians
have more options for these patients. Patients won’t need to wait for a specific
treatment to ensure they are getting the best care no matter where they live.”